NOVIGENIX: AI-POWERED LIQUID BIOPSY FOR PRECISION ONCOLOGY

Novigenix develops AI-driven blood-based diagnostics for cancer, helping personalize treatment and predict immunotherapy response.

“We chose Biopôle for its strong tradition of innovation and cutting‑edge infrastructure, positioning Novigenix at the center of cancer research near renowned institutions such as ISREC, CHUV and the Ludwig Center. It offers an ecosystem where research, technology and product development come together to facilitate groundbreaking innovations making it to market with the chance to ultimately improve patients’ lives.”

Dr. Brian B. Hashemi

Executive Chairman & CEO Novigenix

Novigenix, based at Biopôle, a life science campus within Switzerland Innovation Park West EPFL, is innovating cancer care through its LITOSeek™ platform, an AI-powered, blood-based diagnostic solution that analyzes immune mRNA profiles and tumor DNA to predict cancer presence, treatment response, and potential adverse effects. Unlike traditional biopsies, LITOSeek™ uses a simple blood draw to offer a non-invasive and real-time view of a patient’s immunological status and tumor biology.

This multimodal liquid biopsy approach combines immuno-transcriptomic signatures from whole blood with circulating tumor DNA data. It helps oncologists identify which patients are likely to benefit from immunotherapies, such as checkpoint inhibitors, and who may be at risk for immune-related side effects. The integration of machine learning enhances pattern recognition across thousands of patient samples, improving predictive accuracy over time.

In 2025, Novigenix secured €1.8 million in EU funding through the BRECISE consortium under the Innovative Health Initiative. The funding supports industrialization of LITOSeek™ for broader clinical deployment in Europe, with a focus on prostate and bladder cancers. This builds on Novigenix’s long-standing collaborations with academic hospitals and pharma partners to validate clinical utility and accelerate drug development.

With LITOSeek™, Novigenix is helping transition cancer care from reactive to predictive—offering patients earlier diagnosis, more precise therapy selection, and better outcomes through personalized medicine.

Diese Stories könnten sie auch interessieren